Valuation: Shanghai Rendu Biotechnology Co., Ltd.

Market Cap 202.38Cr 30Cr 27Cr 25Cr 23Cr 43Cr 2.9TCr 43Cr 302.93Cr 117.38Cr 1.48TCr 113.33Cr 110.87Cr 4.76TCr P/E 2024
-179x
P/E 2025 186x
Enterprise Value 120.93Cr 18Cr 16Cr 15Cr 14Cr 26Cr 1.73TCr 26Cr 181.01Cr 70Cr 886.41Cr 68Cr 66Cr 2.84TCr EV / Sales 2024
3.31x
EV / Sales 2025 6.55x
Free-Float
48.41%
Yield 2024
0.56%
Yield 2025 2.38%
29/08 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026 CI
14/05 Shanghai Rendu Biotechnology's share trade to resume from May 15 RE
14/05 Nanjing Haijing Pharmaceutical Co., Ltd. agreed to acquire 21.25% stake in Shanghai Rendu Biotechnology Co., Ltd. from Ju Jinliang, Qiming Weichuang Venture Capital Management Company Limited, Runcong Enterprise Management Center (Limited Partnership), China International Capital Corporation Limited, Qiming Ventures Fund III, Changzhou Jinxin Venture Capital Co., Ltd. and Novel Praise Limited for approximately CNY 520 million. CI
08/05 Rendu Biotech's Controlling Shareholder Eyes Share Transfer Deal MT
07/05 Trading in Shanghai Rendu Biotechnology's shares to halt RE
28/04 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
27/02 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
30/25/30 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
29/25/29 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
29/25/29 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
27/25/27 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
29/24/29 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024 CI
29/24/29 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024 CI
1 day+4.46%
1 week+6.12%
1 month+6.64%
3 months+4.97%
6 months+2.45%
Current year+7.90%
1 week 48.58
Extreme 48.58
55.06
1 month 42.33
Extreme 42.33
55.06
Current year 40
Extreme 40
63.56
1 year 40
Extreme 40
63.56
3 years 22.5
Extreme 22.5
63.56
5 years 22.5
Extreme 22.5
72
10 years 22.5
Extreme 22.5
72
Manager TitleAgeSince
Chief Executive Officer 43 09/12/2022
Chief Tech/Sci/R&D Officer 60 13/06/2007
Director of Finance/CFO 52 01/08/2015
Director TitleAgeSince
Chairman 60 13/06/2007
Director/Board Member 43 01/05/2008
Director/Board Member 61 21/10/2020
Change 5-day change 1-year change 3-year change Capi.($)
+4.46%+6.12%+10.60%+10.01% 30Cr
+0.84%-3.74%-26.69%+1.85% 17TCr
-0.07%-2.55%-9.53%+11.07% 11TCr
+0.90%+1.13%-24.83%+0.58% 11TCr
-1.24%-0.76%-49.04%-12.75% 7.39TCr
-0.24%+0.69%+0.16%+72.58% 5.9TCr
-0.86%+2.96%+13.57%+59.50% 5.13TCr
-0.71%-3.82%-7.72%-31.41% 4.82TCr
+0.12%-0.17%-18.21%+20.29% 4.08TCr
-1.01%-1.45%+28.48%-9.72% 3.22TCr
Average +0.22%-0.10%-8.32%+12.20% 6.9TCr
Weighted average by Cap. +0.03%-1.29%-16.35%+10.13%

Financials

2024 2025
Net sales 18Cr 2.65Cr 2.35Cr 2.19Cr 2Cr 3.77Cr 254.28Cr 3.81Cr 27Cr 10Cr 129.99Cr 9.93Cr 9.72Cr 417.2Cr 16Cr 2.42Cr 2.15Cr 2Cr 1.83Cr 3.44Cr 232.19Cr 3.48Cr 24Cr 9.39Cr 118.7Cr 9.07Cr 8.87Cr 380.95Cr
Net income -78.12L -11.65L -10.35L -10L -9L -16.61L -11Cr -16.76L -1.17Cr -45.31L -5.73Cr -43.75L -42.8L -18Cr 1.01Cr 15.05L 13.37L 12.48L 11.37L 21.45L 14Cr 21.65L 1.51Cr 58.51L 7.39Cr 56.49L 55.26L 24Cr
Net Debt -80Cr -12Cr -11Cr -9.86Cr -8.99Cr -17Cr -1.14TCr -17Cr -119.37Cr -46Cr -584.55Cr -45Cr -44Cr -1.88TCr -81Cr -12Cr -11Cr -10Cr -9.18Cr -17Cr -1.17TCr -17Cr -121.91Cr -47Cr -597.01Cr -46Cr -45Cr -1.92TCr
Logo Shanghai Rendu Biotechnology Co., Ltd.
Shanghai Rendu Biotechnology Co Ltd is a China-based company mainly engaged in the research, development, production, and sales of molecular diagnostic reagents and equipment. The Company mainly operates three businesses. The reagent business is mainly engaged in the research, development, production, and sales of molecular diagnostic reagents for reproductive tract infections, respiratory tract infections, enteroviruses, and bloodborne infectious diseases, as well as other reagent products such as sample preservation solutions and nucleic acid extraction reagents. The instrument business is mainly engaged in the research, development, production, and sales of molecular diagnostic instruments such as the fully automated nucleic acid detection and analysis system (AutoSAT). The testing business is mainly engaged in the provision of clinical testing services, including pathogen detection for the genitourinary system, bloodborne pathogens, respiratory system, and digestive system.
Employees
235
Date Price Change Volume
30/26/30 CN¥52.19 +4.46% 9,93,614
29/26/29 CN¥49.96 +2.34% 5,96,074
28/26/28 CN¥48.82 -0.73% 3,83,517
24/26/24 CN¥49.18 +0.57% 4,28,773
  1. Stock Market
  2. Stocks
  3. 688193 Stock